CSPC PHARMA (01093): Arbidol Injection Receives Drug Registration Approval

CSPC PHARMA (01093) announced that the company's developed Aripiprazole Injection (4.4ml:32mg) has obtained the drug registration approval from the National Medical Products Administration of the People's Republic of China. This product is a new generation NK-1 receptor antagonist, which is a submicron injection that can selectively bind to and antagonize substance P in the brain to effectively prevent acute and delayed vomiting. The product is suitable for preventing postoperative nausea and vomiting (PONV) in adults. Compared to traditional forms of Aripiprazole, this product works quickly, significantly improves patient compliance, and effectively reduces the occurrence of allergic reactions in clinical use, providing a better medication option for preventing postoperative nausea and vomiting in adults. In September 2024, the company's developed Aripiprazole Injection (18ml:130mg) has also obtained the drug registration approval and is mainly used for preventing chemotherapy-induced nausea and vomiting. The successful approval of this product further enhances the company's competitiveness in the anti-emetic field.